Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen S Slobod

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Viral Immunology|April 15, 2020
How Basic Immunological Principles May Instruct the Design of a Successful HIV-Type 1 VaccineKaren S Slobod, Julia L Hurwitz
Leukemia & Lymphoma|April 15, 2003
Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?Sybil D'Costa, Karen S Slobod, Julia L Hurwitz
Transplantation|September 16, 2003
Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporineXiaoyan Zhan, Brita Brown, Karen S Slobod, et al.
AIDS Research and Human Retroviruses|April 7, 2007
HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulationsXiaoyan Zhan, Julia L Hurwitz, Scott A Brown, et al.
Current Drug Targets. Infectious Disorders|July 16, 2005
The HIV pandemic: a forgotten crisis?Maxwell Madzikanga, Abigail Kangwende, John Pfumojena, et al.
Current Drug Targets. Infectious Disorders|June 25, 2005
CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?Scott A Brown, Julia L Hurwitz, Xiaoyan Zhan, et al.
Expert Review of Vaccines|July 20, 2005
HIV vaccines: brief review and discussion of future directionsKaren S Slobod, Mattia Bonsignori, Scott A Brown, et al.
Vaccine|March 9, 2004
Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cellsXiaoyan Zhan, Karen S Slobod, Sherri Surman, et al.
Current Drug Targets. Infectious Disorders|June 25, 2005
Application of the polyvalent approach to HIV-1 vaccine developmentJulia L Hurwitz, Karen S Slobod, Tim D Lockey, et al.
AIDS Research and Human Retroviruses|October 31, 2002
A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?Timothy D Lockey, Sherri Surman, Scott Brown, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Viral Immunology|April 15, 2020
How Basic Immunological Principles May Instruct the Design of a Successful HIV-Type 1 VaccineKaren S Slobod, Julia L Hurwitz
Leukemia & Lymphoma|April 15, 2003
Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?Sybil D'Costa, Karen S Slobod, Julia L Hurwitz
Transplantation|September 16, 2003
Inhibition of ex vivo-expanded cytotoxic T-lymphocyte function by high-dose cyclosporineXiaoyan Zhan, Brita Brown, Karen S Slobod, et al.
AIDS Research and Human Retroviruses|April 7, 2007
HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulationsXiaoyan Zhan, Julia L Hurwitz, Scott A Brown, et al.
Current Drug Targets. Infectious Disorders|July 16, 2005
The HIV pandemic: a forgotten crisis?Maxwell Madzikanga, Abigail Kangwende, John Pfumojena, et al.
Current Drug Targets. Infectious Disorders|June 25, 2005
CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?Scott A Brown, Julia L Hurwitz, Xiaoyan Zhan, et al.
Expert Review of Vaccines|July 20, 2005
HIV vaccines: brief review and discussion of future directionsKaren S Slobod, Mattia Bonsignori, Scott A Brown, et al.
Vaccine|March 9, 2004
Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cellsXiaoyan Zhan, Karen S Slobod, Sherri Surman, et al.
Current Drug Targets. Infectious Disorders|June 25, 2005
Application of the polyvalent approach to HIV-1 vaccine developmentJulia L Hurwitz, Karen S Slobod, Tim D Lockey, et al.
AIDS Research and Human Retroviruses|October 31, 2002
A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?Timothy D Lockey, Sherri Surman, Scott Brown, et al.
Pageof 4